Related Experiment Videos
Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy
A Kataoka1, H Imai, S Inayoshi
1Third Department of Internal Medicine, Oita Medical University, Japan.
Insights
High-dose vitamin C therapy shows promise for treating human T-lymphotropic virus type I-associated myelopathy (HAM). This treatment improved patient disability scores and demonstrated favorable immunomodulatory effects without significant side effects.
Area of Science:
- Neurology
- Immunology
- Nutritional Science
Background:
- Human T-lymphotropic virus type I-associated myelopathy (HAM) is a debilitating neurological disorder.
- Current treatment options for HAM are limited, necessitating exploration of novel therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy and safety of intermittent high-dose vitamin C therapy in patients with HAM.
- To assess the impact of vitamin C on disability scores and specific biomarkers in HAM patients.
Main Methods:
- A study involving seven patients diagnosed with HAM.
- Intermittent high-dose vitamin C therapy administered to all participants.
- Assessment of disability scores and serum immunosuppressive acidic protein levels before and after treatment.
Main Results:
- All seven HAM patients responded positively to vitamin C therapy, with no serious adverse events reported.
- Significant improvement in the grade of disability score, decreasing from 7.1 to 3.6 (p < 0.01).
- Serum immunosuppressive acidic protein levels decreased significantly post-therapy (from 747 to 398 µg/ml, p < 0.05), indicating a favorable immunomodulatory effect.
Conclusions:
- Intermittent high-dose vitamin C therapy is a safe and effective treatment for HAM.
- Vitamin C therapy demonstrates potential immunomodulatory benefits in managing HAM.
- Further research is warranted to explore the long-term effects and mechanisms of vitamin C in HAM treatment.
Abstract:
The efficacy of intermittent high-dose vitamin C therapy was evaluated in seven patients with HTLV-I-associated myelopathy (HAM). All HAM patients responded well to this therapy without serious side effects. Grade of disability score improved at 9.7 (SD 5.8) months after the therapy from 7.1 (3.3) to 3.6 (2.0) (p < 0.01). Serum immunosuppressive acidic protein was elevated before and decreased after the therapy from 747 (316) to 398 (86) micrograms/ml (p < 0.05), suggesting favourable immunomodulatory action of vitamin C therapy in HAM patients.